1189436-83-6 Usage
Description
N-Boc-N-methylpiperazine-d8, with the CAS number 1189436-83-6, is a compound that is utilized in the field of organic synthesis. It is characterized by its colorless oil appearance, which indicates its potential for use in various chemical reactions and processes.
Uses
Used in Organic Synthesis:
N-Boc-N-methylpiperazine-d8 is used as a synthetic building block for the creation of more complex organic molecules. Its unique structure allows it to be a valuable component in the synthesis of various compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-Boc-N-methylpiperazine-d8 is used as an intermediate in the development of new drugs. Its incorporation into drug molecules can potentially enhance their pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Research and Development:
N-Boc-N-methylpiperazine-d8 is also employed in research and development settings, where it can be used to study the properties and behavior of various organic compounds. This can lead to a better understanding of their mechanisms of action and potential applications in various fields.
Used in Chemical Analysis:
Due to its colorless oil nature, N-Boc-N-methylpiperazine-d8 can be used in chemical analysis to serve as a reference or standard for the identification and quantification of other compounds. This can be particularly useful in quality control and assurance processes within the chemical and pharmaceutical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1189436-83-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,9,4,3 and 6 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1189436-83:
(9*1)+(8*1)+(7*8)+(6*9)+(5*4)+(4*3)+(3*6)+(2*8)+(1*3)=196
196 % 10 = 6
So 1189436-83-6 is a valid CAS Registry Number.
1189436-83-6Relevant articles and documents
DEUTERIUM-MODIFIED BRIGATINIB DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF
-
Paragraph 0180; 0182, (2018/10/15)
The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.
